Apogee Therapeutics slides as investors absorb March $403 million stock offering dilution
Apogee Therapeutics (APGE) is down about 3% on April 24, 2026, as the market digests its recently completed large equity raise. Shares are under pressure from dilution/extra float following a ~$403 million underwritten offering priced at $70 per share in late March.
1. What’s moving the stock
Apogee Therapeutics shares are trading lower today as investors continue to reposition after the company’s recent equity financing, a common source of near-term pressure for biotech stocks. The hangover typically comes from dilution, incremental tradable supply from newly issued shares, and short-term arbitrage activity tied to deal allocations and hedges.
2. The financing overhang in focus
Apogee completed an underwritten public offering in late March, selling 5.75 million shares at $70.00 per share for gross proceeds of about $403 million. Even when a raise strengthens the balance sheet, the added share count and expected selling by some deal participants can weigh on the stock in subsequent sessions.
3. What to watch next
Traders will likely watch for stabilization in volume and any follow-through disclosures that clarify how the company plans to deploy the new capital and how far it extends the cash runway. Separately, any additional insider transaction filings can influence sentiment around post-offering price action.